Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
Int J Cardiol ; 323: 281-284, 2021 01 15.
Article in English | MEDLINE | ID: covidwho-753509

ABSTRACT

INTRODUCTION: COVID-19 infection is commonly complicated with pro-thrombotic state and endothelial dysfunction. While several studies reported a high incidence of venous thromboembolic events. The occurrence of arterial thromboses are yet rarely described and could be underestimated. OBJECTIVES: To describe the clinical and biological characteristics of COVID-19 patients presenting with an associated arterial thromboembolic event. MATERIAL AND METHODS: We performed a retrospective multicentric study in 3 centers between France and Italy. All patients with a confirmed SARS-CoV-2 infection and arterial thromboembolic events were included in the analysis. RESULTS: From March 8th to April 25th 2020, we identified 20 patients (24 events) with arterial thromboembolic events over 209 admitted patients (9.6%) with severe COVID-19 infection. Arterial thrombotic events included acute coronary occlusions (n = 9), stroke (n = 6), limb ischemia (n = 3), splenic infarcts (n = 3), aortic thrombosis (n = 2) and occlusive mesenteric ischemia (n = 1). At the time of the event, 10/20 (50%) of patients received thromboprohylaxis, 2/20 (10%) were receiving treatment dose anticoagulation and 5/20 (25%) were receiving antiplatelet therapy. CONCLUSION: Our observations suggest that serious arterial thrombotic events might occur in Covid-19 patients. However, the exact incidence of such events and the best way to prevent them yet remains to be investigated.


Subject(s)
COVID-19/complications , Coronary Occlusion/virology , Ischemia/virology , Mesenteric Ischemia/virology , Splenic Infarction/virology , Stroke/virology , Thrombosis/virology , Aged , Anticoagulants/therapeutic use , Aorta , Extremities/blood supply , Female , France/epidemiology , Humans , Italy/epidemiology , Male , Middle Aged , Platelet Aggregation Inhibitors/therapeutic use , Retrospective Studies , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL